WeVote
Log In

Bill

Bill

S 853

Establishes the New York manufacturing adequate domestic equipment credit (NY MADE)

2025 Regular Session Introduced by George Borrello and 4 co-sponsors

MassHealth vaccine administration reimbursement rates for Medicaid-eligible adults and children must be at least CMS regional rates, effective Jan 1, 2026.

REFERRED TO BUDGET AND REVENUE
0
WeVote Research Nonpartisan
Bill Summary · S 853

Bill Summary — S 853

Note on source materials
- The materials provided include several different and inconsistent texts and metadata (a Massachusetts Senate docket text, a federal “INNOVATE Act” table of contents, and a title referencing a New York tax credit). Below I summarize the concrete bill text that appears in the submitted “Bill Text” (Massachusetts Senate Docket No. 1782) and also note the other materials so readers understand the discrepancies.

Primary operative text (Massachusetts — “An Act preserving and protecting public health”)

  • Jurisdiction: Commonwealth of Massachusetts
  • Sponsor shown in docket: Sal N. DiDomenico (Middlesex and Suffolk)
  • Effective date: January 1, 2026
  • Where added: Chapter 118E of the Massachusetts General Laws (Health Care Financing)

Main purpose

Require that vaccine administration reimbursement rates for Medicaid-eligible adults and children in Massachusetts be no less than the Centers for Medicare & Medicaid Services (CMS) regional reimbursement rate.

Key provisions

  • Adds new Section 83 to Chapter 118E.
  • Mandates that vaccine administration reimbursement rates for all providers administering immunizations to Medicaid-eligible adults and children shall be at least equal to the CMS regional reimbursement rate.
  • Explicitly covers billing through any Massachusetts Medicaid immunization payment providers or pharmacy benefit manager (PBM).
  • Effective January 1, 2026.

Who would be affected

  • Medicaid-eligible patients (adults and children) — potentially greater access to immunization services if provider participation increases.
  • Providers who administer vaccines: physicians, clinics, community health centers, pharmacies, and other immunization providers — would receive at least CMS regional rates for administration.
  • Pharmacy benefit managers and Medicaid immunization payment vendors — required to apply the reimbursement floor when processing claims.
  • Massachusetts Medicaid (MassHealth) budget and state fiscal planning — likely increased Medicaid spending depending on current state rates versus CMS regional rates.

Potential impacts and considerations

  • Provider participation: Raising the floor to CMS regional rates may increase willingness of providers (especially pharmacies and smaller clinics) to deliver vaccines to Medicaid patients.
  • Fiscal impact: If current Massachusetts Medicaid vaccine administration rates are below CMS regional rates, the change would increase state Medicaid expenditures. Exact fiscal effect would depend on the gap between current rates and CMS regional rates and on vaccine utilization volumes.
  • Administrative/operational: State Medicaid and contracted PBMs would need to implement the reimbursement floor in claims processing systems prior to the effective date.

Other texts included in the submission (not part of the Massachusetts bill text)

  • “INNOVATE Act” (federal) — table of contents referencing SBIR/STTR program reforms, research security measures, and commercialization/administration changes. No complete text was included, only headings.
  • Title mentioning “Establishes the New York manufacturing adequate domestic equipment credit (NY MADE)” — no substantive NY tax-credit text provided.
  • Sponsors listed (Joni Ernst, Patrick Gallivan, others) appear to be inconsistent with the Massachusetts docket sponsor and likely relate to a different bill.

Procedural status (as provided)

  • Mixed entries in the supplied legislative actions (referrals to various committees, hearings). The docketed Massachusetts bill text shows filing on 1/16/2025 and an effective date provision; other listed actions (committee referrals, hearings) appear inconsistent and may refer to other versions or jurisdictions. Confirm current status with the official Massachusetts Legislature website or clerk for the accurate docket and history.

If you want, I can:
- Pull and summarize the official current legislative history and fiscal note (Massachusetts) for this bill, or
- Prepare a summary focused on the INNOVATE Act (SBIR/STTR reforms) if you provide the full text.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.